» Articles » PMID: 25448552

Development of an Ultrasound Sensitive Oxygen Carrier for Oxygen Delivery to Hypoxic Tissue

Overview
Journal Int J Pharm
Specialties Chemistry
Pharmacology
Date 2014 Dec 3
PMID 25448552
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Radiation therapy is frequently used in the treatment of malignancies, but tumors are often more resistant than the surrounding normal tissue to radiation effects, because the tumor microenvironment is hypoxic. This manuscript details the fabrication and characterization of an ultrasound-sensitive, injectable oxygen microbubble platform (SE61O2) for overcoming tumor hypoxia. SE61O2 was fabricated by first sonicating a mixture of Span 60 and water-soluble vitamin E purged with perfluorocarbon gas. SE61O2 microbubbles were separated from the foam by flotation, then freeze dried under vacuum to remove all perfluorocarbon, and reconstituted with oxygen. Visually, SE61O2 microbubbles were smooth, spherical, with an average diameter of 3.1 μm and were reconstituted to a concentration of 6.5 E7 microbubbles/ml. Oxygen-filled SE61O2 provides 16.9 ± 1.0 dB of enhancement at a dose of 880 μl/l (5.7 E7 microbubbles/l) with a half-life under insonation of approximately 15 min. In in vitro release experiments, 2 ml of SE61O2 (1.3 E8 microbubbles) triggered with ultrasound was found to elevate oxygen partial pressures of 100ml of degassed saline 13.8 mmHg more than untriggered bubbles and 20.6 mmHg more than ultrasound triggered nitrogen-filled bubbles. In preliminary in vivo delivery experiments, triggered SE61O2 resulted in a 30.4 mmHg and 27.4 mmHg increase in oxygen partial pressures in two breast tumor mouse xenografts.

Citing Articles

Biochemical hallmarks-targeting antineoplastic nanotherapeutics.

Han J, Dong H, Zhu T, Wei Q, Wang Y, Wang Y Bioact Mater. 2024; 36:427-454.

PMID: 39044728 PMC: 11263727. DOI: 10.1016/j.bioactmat.2024.05.042.


Oxygen generating biomaterials at the forefront of regenerative medicine: advances in bone regeneration.

Zhao J, Zhou C, Xiao Y, Zhang K, Zhang Q, Xia L Front Bioeng Biotechnol. 2024; 12:1292171.

PMID: 38282892 PMC: 10811251. DOI: 10.3389/fbioe.2024.1292171.


Sonosensitive Cavitation Nuclei-A Customisable Platform Technology for Enhanced Therapeutic Delivery.

Lyons B, Balkaran J, Dunn-Lawless D, Lucian V, Keller S, OReilly C Molecules. 2023; 28(23).

PMID: 38067464 PMC: 10708135. DOI: 10.3390/molecules28237733.


Improved Tumor Control Following Radiosensitization with Ultrasound-Sensitive Oxygen Microbubbles and Tumor Mitochondrial Respiration Inhibitors in a Preclinical Model of Head and Neck Cancer.

Lacerda Q, Falatah H, Liu J, Wessner C, Oeffinger B, Rochani A Pharmaceutics. 2023; 15(4).

PMID: 37111787 PMC: 10145368. DOI: 10.3390/pharmaceutics15041302.


Oxygen therapy alternatives in COVID-19: From classical to nanomedicine.

Pereira L, Dallagnol C, Moulepes T, Hirota C, Kutsmi P, Dos Santos L Heliyon. 2023; 9(4):e15500.

PMID: 37089325 PMC: 10106793. DOI: 10.1016/j.heliyon.2023.e15500.


References
1.
Forsberg F, Basude R, Liu J, Alessandro J, Shi W, Rawool N . Effect of filling gases on the backscatter from contrast microbubbles: theory and in vivo measurements. Ultrasound Med Biol. 1999; 25(8):1203-11. DOI: 10.1016/s0301-5629(99)00079-4. View

2.
Richard D, Berra E, Pouyssegur J . Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun. 1999; 266(3):718-22. DOI: 10.1006/bbrc.1999.1889. View

3.
Basude R, Duckworth J, Wheatley M . Influence of environmental conditions on a new surfactant-based contrast agent: ST68. Ultrasound Med Biol. 2000; 26(4):621-8. DOI: 10.1016/s0301-5629(99)00151-9. View

4.
Basude R, Wheatley M . Generation of ultraharmonics in surfactant based ultrasound contrast agents: use and advantages. Ultrasonics. 2002; 39(6):437-44. DOI: 10.1016/s0041-624x(01)00080-4. View

5.
Miller A, Nanda N . Contrast echocardiography: new agents. Ultrasound Med Biol. 2004; 30(4):425-34. DOI: 10.1016/j.ultrasmedbio.2003.12.002. View